NEWS
-
NEWS
Iwamiya, Metcela’s co-CEO, spoke at ACCJ x LINK-J event: “The Front Line of the Regenerative Medicine Business: Practical Application of Cell Medicine”
One of our Co-CEO, Iwamiya, spoke at an event hosted by The American Chamber of Commerce in Japan (ACCJ) and supported by the Life Science Innovation Network Japan (LINK-J).
-
NEWS
Metcela announces issuance of second Japanese patent covering fibroblast-based cell therapy for the treatment of heart diseases
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announces that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6618066 to support the company’s technology of VCF (VCAM-1-positive Cardiac Fibroblast).
